Mercados españoles cerrados en 4 hrs 55 min

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
270,04-2,16 (-0,79%)
Al cierre: 4:00PM EDT

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617 679 2000
http://www.biogen.com

Sector(es)Healthcare
SectorDrug Manufacturers—General
Empleados a tiempo completo7.400

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Michel VounatsosCEO & Director5,72MN/A1962
Ms. Susan H. AlexanderExec. VP, Chief Legal Officer & Sec.1,99M1,77M1957
Dr. Alfred W. Sandrock Jr.Exec. VP of R&D1,87MN/A1958
Mr. Chirfi GuindoExec. VP of Global Product Strategy & Commercialization1,32MN/A1966
Mr. Michael R. McDonnellExec. VP & CFON/AN/A1964
Los importes son a partir de 31 de diciembre de 2019 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Biogen Inc., a día 9 de diciembre de 2019, es 4. Las puntuaciones base son Auditoría: 1; Tablero: 6; Derechos de los accionistas: 2; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.
Al usar Yahoo aceptas que Yahoo y sus socios puedan utilizar cookies para personalización y otros fines